Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy
This article was originally published in RPM Report
The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.
You may also be interested in...
The pharmaceutical industry didn’t have as much at stake in the second major Supreme Court ruling on the Affordable Care Act – but should still be celebrating the decision to upheld the Administration’s approach to exchanges.
Visits from HHS Secretary Sebelius raise the question of whether Texas could change its mind and expand Medicaid eligibility under the ACA.
Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.